Therapeutic approaches involving PGM3 inhibition, and possibly inhibition of protein O-GlcNAcylation, in combination with GEM could be promising to bypass the drug resistance in pancreatic cancer. This evidence concerns the gene PGM3 and familial pancreatic carcinoma.